Opioid Alternative Articles & Analysis
12 news found
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, ...
” Researchers used cells from humans and mice with inammatory bowel disease, which can cause chronic pain, in order to facilitate the study. The body’s opioid receptors relieve pain when they are activated by opioids and the majority of these medications act on the mu opioid receptor. However, for purposes of the current study, ...
These data suggest that cebranopadol has a lower potential for abuse versus both C-II and C-IV opioids. Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain. ...
BioWave’s technology has helped professional and college athletes, veterans and others suffering from chronic pain, get closer to a pain-free life and return to daily activities without the use of opioids. BioWave recently introduced a new patent pending product family called BioWraps which are wearable compression electrode garments that are paired with BioWave’s ...
In the past decade, pharmaceutical companies have been reluctant to re-address pain treatments following the opioids crisis. However, we see a change on the horizon. Neuropathix has designated proprietary, cannabinoid-derivative compound KLS-13019 as lead drug candidate for the treatment of neuropathic pain, a viable alternative to opioids. ...
REBORN1©, if successful, is expected to provide proof of concept evidence that QIXLEEF™ can be an alternative to the class of immediate release oral opioids in the management of breakthrough cancer pain. ...
The published results can be accessed here: ECAP-Controlled Closed-Loop Spinal Cord Stimulation Efficacy and Opioid Reduction over 24-Months: Final Results of the Prospective, Multicenter, Open-Label Avalon Study In publishing these results, Evoke has set a new standard for clinical studies of SCS therapy evaluating patients through 24 months. Outcome measures in the Avalon ...
Formulated for subcutaneous delivery, Bexson's ketamine-based pain therapy aims to be an alternative to opioids. The patent is directed to Bexson's ketamine formulation that is specifically tuned to the pH and osmolality of subcutaneous tissue, and applies to racemic ketamine, as well as the R or S enantiomers. ...
Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of financing. Funding will support the company through pre-clinical and GMP manufacturing scale up for its proprietary ketamine formulation, BB106, and the development of a wearable ...
In 2018, Europe was responsible for 23.2 percent of the world’s pharmaceutical sales.1 The size of the market in the European Union Five is expected to grow by 25 percent between 2017-2022,2 with experts predicting the market will reach over $226 billion in total from pharmaceutical market sales.3 “We have a very live and viable leading drug candidate in KLS-13019, which is a ...
The pre-clinical grant study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative in the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN). ...
The funding from this will support us in our goal to provide an alternative to opioids for managing pain,” said Richard Hanbury, founding CEO of Sana Health. ...